- Home
- » Tags
- » Teriflunomide
Top View
- Tysabri® (Natalizumab Injection for Intravenous Use – Biogen)
- COMPARISON of the WHO ATC CLASSIFICATION & Ephmra/Intellus Worldwide ANATOMICAL CLASSIFICATION
- Aubagio® (Teriflunomide)
- Lemtrada (Alemtuzumab)
- Multiple Sclerosis Agents Aubagio® (Teriflunomide) Gilenya® (Fingolimod) Mayzent® (Siponimod) Tecfidera® (Dimethyl Fumarate) Zeposia® (Ozanimod) Effective 01/01/2021
- Role of Disease-Modifying Oral Drugs in Multiple Sclerosis: a Systematic Review with Meta-Analysis
- Florencio Zaragoza Dörwald Lead Optimization for Medicinal Chemists
- Cutaneous Side Effects of First / Second Line Oral Disease - Modifying Treatments in Patients with Multiple Sclerosis
- Switch Analysis of Teriflunomide from Other Multiple Sclerosis Disease Modifying Therapies Ronald O
- AUBAGIO Safely and • Effectively
- Comparative Effectiveness of Teriflunomide and Dimethyl
- Multiple Sclerosis and SARS-Cov-2 Vaccination: Considerations for Immune-Depleting Therapies
- INITIATING ORAL AUBAGIO® (Teriflunomide) THERAPY
- In This Issue
- 8/15/2020 Code(S): HCPCS J2323 SUBJECT: Tysabri (Natalizumab)
- Comparative Effectiveness of Teriflunomide Vs Dimethyl Fumarate in Multiple Sclerosis David-Axel Laplaud, Romain Casey, Laetitia Barbin, Et Al
- Summary Review
- Immunology Research Product Listing | Edition 2
- For Relapsing Forms of Multiple Sclerosis
- Amended Clinical Trial Protocol No. 04
- Medication Guidelines for Solid Organ Transplants
- Oral Multiple Sclerosis Drugs
- Aubagio, INN-Teriflunomide
- 202992Orig1s000
- Assessment Report
- Hematological Alterations Related to Treatment with Teriflunomide And
- Pregnancy Registries
- For Multiple Sclerosis
- Efficacy and Safety of Ponesimod Compared to Teriflunomide in Patients with Relapsing Multiple Sclerosis: Results of the Randomi
- DHODH and Cancer: Promising Prospects to Be Explored
- A Report on Comparative Safety and Efficacy of Ponesimod in the Treatment of Multiple Sclerosis (MS)
- WO 2015/150995 Al 8 October 2015 (08.10.2015) P O P C T
- Teriflunomide Drug Monograph
- Guidelines for ATC Classification and DDD Assignment 2021
- Janssen Announces U.S. FDA Approval of PONVORY™ (Ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Pro…
- Tysabri® (Natalizumab) Injection
- New Directions in MS Therapeutics: Vehicles of Hope
- Teriflunomide Tablets 7Mg and 14Mg 7 & 14
- Thalidomide - Wikipedia, the Free Encyclopedia
- Relapsing Remitting Multiple Sclerosis: Treatment Update Outline
- Multiple Sclerosis Agents Aubagio® (Teriflunomide) Bafiertam
- Detailed Background and Justification for Good Practice Statements and Recommendations for Medication
- Ozanimod 0.23Mg, 0.46Mg and 0.92Mg Hard Capsules (Zeposia®) Celgene Ltd
- A Randomized, Blinded, Parallel-Group, Pilot Trial of Mycophenolate Mofetil (Cellcept) Compared with Interferon Beta-1A (Avonex)
- Comparable Efficacy and Safety of Teriflunomide Versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis
- Discontinuation of Teriflunomide and Dimethyl Fumarate in a Large Italian Multicentre Population: a 24-Month Real-World Experience
- HIGHLIGHTS of PRESCRIBING INFORMATION PONVORYTM (Ponesimod) Tablets These Highlights Do Not Include All the Information Needed to Use PONVORY Safely and Effectively
- A Multiple Sclerosis Perspective
- GILENYA (Fingolimod) MAVENCLAD (Cladrabine) MAYZENT (Siponimod) PONVORY (Ponesimod) TECFIDERA (Dimethyl Fumarate) VUMERITY (Diroximel Fumarate) ZEPOSIA (Ozanimod)
- Ocrevus (Ocrelizumab), and Tysabri (Natalizumab) Step Therapy – Medicare Part B
- Ocular Side Effects of Antirheumatic Medications: a Qualitative Review
- CDR Clinical Review Report – Teriflunomide (Aubagio)
- 213498Orig1s000